The cannabinoid system and its pharmacological manipulation - a review, with emphasis upon the uptake and hydrolysis of anandamide

被引:48
作者
Fowler, Christopher J. [1 ]
机构
[1] Umea Univ, Dept Pharmacol & Clin Neurosci, SE-90187 Umea, Sweden
关键词
anandamide; cannabinoid; fatty acid amide hydrolase; therapeutic potential;
D O I
10.1111/j.1472-8206.2006.00442.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Although cannabis has been used both recreationally and for medicinal purposes since ancient times, it was not until the 1990s that the receptors responsible for many of the actions of Delta(9)-tetrahydrocannabinol, the main psychoactive ingredient of cannabis, were cloned. Since then, our knowledge of the endogenous cannabinoid system, its physiology, pharmacology and therapeutic potential have expanded enormously. In the present review, the cannabinoid system is described, with particular emphasis on the mechanisms of removal and metabolism of the endocannabinoid signalling molecule anandamide. The current literature shows that cells can accumulate anandamide, and that this process can be disrupted pharmacologically, but that the nature of the mechanism(s) involved remains a matter of some debate. The main enzyme for the hydrolysis of anandamide, fatty acid amide hydrolase, is well characterized, and molecules selectively inhibiting this enzyme have potential therapeutic utility in a number of areas, in particular for the treatment of pain conditions.
引用
收藏
页码:549 / 562
页数:14
相关论文
共 167 条
[31]  
Clement AB, 2003, J NEUROSCI, V23, P3916
[32]  
Compton DR, 1997, J PHARMACOL EXP THER, V283, P1138
[33]  
COSTA B, 2005, S CANN INT CANN RES, P33
[34]   Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides [J].
Cravatt, BF ;
Giang, DK ;
Mayfield, SP ;
Boger, DL ;
Lerner, RA ;
Gilula, NB .
NATURE, 1996, 384 (6604) :83-87
[35]   Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase [J].
Cravatt, BF ;
Demarest, K ;
Patricelli, MP ;
Bracey, MH ;
Giang, DK ;
Martin, BR ;
Lichtman, AH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (16) :9371-9376
[36]   Functional disassociation of the central and peripheral fatty acid amide signaling systems [J].
Cravatt, BF ;
Saghatelian, A ;
Hawkins, EG ;
Clement, AB ;
Bracey, MH ;
Lichtman, AH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (29) :10821-10826
[37]   CONFORMATIONALLY RESTRAINED ANALOGS OF PRAVADOLINE - NANOMOLAR POTENT, ENANTIOSELECTIVE, (AMINOALKYL)INDOLE AGONISTS OF THE CANNABINOID RECEPTOR [J].
DAMBRA, TE ;
ESTEP, KG ;
BELL, MR ;
EISSENSTAT, MA ;
JOSEF, KA ;
WARD, SJ ;
HAYCOCK, DA ;
BAIZMAN, ER ;
CASIANO, FM ;
BEGLIN, NC ;
CHIPPARI, SM ;
GREGO, JD ;
KULLNIG, RK ;
DALEY, GT .
JOURNAL OF MEDICINAL CHEMISTRY, 1992, 35 (01) :124-135
[38]   In vivo pharmacological actions of two novel inhibitors of anandamide cellular uptake [J].
de Lago, E ;
Ligresti, A ;
Ortar, G ;
Morera, E ;
Cabranes, A ;
Pryce, G ;
Bifulco, M ;
Baker, D ;
Fernandez-Ruiz, J ;
Di Marzo, V .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2004, 484 (2-3) :249-257
[39]   UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders [J].
de Lago, E ;
Fernández-Ruiz, J ;
Ortega-Gutiérrez, S ;
Cabranes, A ;
Pryce, G ;
Baker, D ;
López-Rodríguez, M ;
Ramos, JA .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2006, 16 (01) :7-18
[40]   UCM707, a potent and selective inhibitor of endocannabinoid uptake, potentiates hypokinetic and antinociceptive effects of anandamide [J].
de Lago, E ;
Fernández-Ruiz, J ;
Ortega-Gutiérrez, S ;
Viso, A ;
López-Rodríguez, ML ;
Ramos, JA .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2002, 449 (1-2) :99-103